As pharmaceutical companies race to adopt artificial intelligence (AI) to speed up drug development and discovery, the biggest opportunity is not speed, but better clinical and development decisions -- the kind that make late-phase failure rare rather than just faster.
Clinicians, researchers, business leaders – we’ve all become obsessed with AI automation.
Open any industry journal or attend any healthcare conference today, and you will find an overwhelming focus on productivity. The conversation surrounding AI in pharma is dominated by a single question: How can AI do what humans already do, but faster?
But this is short-sighted. There are two kinds of AI.
- The first is AI that automates existing work; activities like writing emails, providing rote chatbot answers, auto-dialing clinical trial enrollees, and matching patient claims.
- The second kind of AI is AI that expands human decision-making. It’s capable of predicting trial outcomes, identifying patient populations, optimizing protocols, recommending interventions, and even personalizing treatment.
The latter is what excites me as a clinician, researcher, and technologist.
The real opportunity is decision intelligence
The fundamental challenge of modern drug development isn’t a lack of information; it’s an abundance of it. Despite decades of advances in biology, computation, and trial design, fewer than one in ten compounds that enter Phase 1 reach approval. Much of that attrition occurs in later, larger trials due to inadequate efficacy, when the trials are most costly and enroll the most patients. Every day, clinical development teams are buried under an avalanche of disparate data streams:
- Multicenter clinical trial data
- Real-world evidence (RWE)
- Continuous patient-reported outcomes (PROs)
- Complex biomarkers and deep genomics
- Market and epidemiological trends
- Patient-generated information
No human mind, nor any isolated team of experts, can realistically synthesize these billions of data points in real time to see the hidden correlations. The challenge of the modern CEO and Chief Medical Officer is making sense of data.
This is where the paradigm shifts from automation to intelligence. The most valuable AI isn't the AI that replaces human effort; it’s the AI that expands human decision-making.
It is the tool that helps clinical leaders predict trial outcomes, identify highly specific patient sub-populations, optimize complex protocols before a single patient is randomized, and recommend adaptive interventions.
The most valuable AI helps us make high-stakes choices we simply couldn't make on our own. Recent late-phase oncology readouts have shown how a strong signal in defined sub-populations can be obscured at the aggregate level. Every failed late-phase trial exposes hundreds or thousands of participants to a therapy that did not work, and a meaningful fraction of those failures were foreseeable from what was already known when the trial was designed.
Why static development no longer works
Historically, clinical development in biopharma organizations has operated as a rigid, sequential assembly line: Design. Recruit. Execute. Analyze.
We locked a protocol into place, spent years and millions of dollars running the trial, and crossed our fingers until the end of the study to finally understand what happened. If the hypothesis was flawed, we only find out after the capital was spent. Clinical trials already apply the logic of futility through interim analyses that halt a study once the data show it is unlikely to succeed, sparing later participants a futile exposure. That same logic should be applied earlier -- before the first patient is enrolled. Just as launching a pivotal trial without a prospective power calculation is now indefensible, initiating one without a quantified, calibrated estimate of its probability of technical success should, in time, become difficult to justify.
This static approach is becoming obsolete. By leveraging advanced AI, there is the possibility of continuous learning throughout the development lifecycle.
Instead of waiting for a retrospective post-mortem, AI acts as a live navigational system, allowing innovators to see patterns as they emerge and dynamically adapt. It shifts the industry from a culture of "execute and pray" to one of continuous, data-driven optimization.
Real-world data closes the loop
The shift toward continuous learning fundamentally alters the traditional lifecycle of a drug.
Previously, a thick wall existed between clinical development and commercialization. Once a drug was approved and entered the market, the development team’s job was largely done.
But AI and real-world data (RWD) completely dissolve that wall. Once a therapy enters the market, real-world patient outcomes, side-effect profiles, and compliance data become an active, ongoing source of intelligence. This creates a powerful feedback loop.
The insights gained from actual patients sitting in doctors' offices flow directly back into the lab, drastically improving future study designs, refining patient selection criteria, and sharpening overall treatment strategies. Development no longer ends at approval; it evolves – but so do expectations.
Precision medicine becomes practical
Precision medicine has been a buzzword for years — a noble goal that so far proves incredibly difficult to scale. But true precision medicine doesn't mean manufacturing millions of bespoke, hyper-individualized drugs for single patients. It means achieving a much better, highly sophisticated match between the patients who exist and the therapies that already work.
Think of how advanced recommendation engines like Google or TikTok seamlessly personalize content for billions of users by understanding their subtle preferences and behaviors.
In a similar, but far more rigorous way, AI can synthesize a patient's genetic, clinical, and lifestyle profile to help physicians personalize treatment decisions.
This is an achievement that neither a human nor an AI algorithm can accomplish in isolation. It requires the raw computing power of AI to synthesize the complexity, paired with the empathy, ethics, and clinical judgment of an expert decision-maker.
Shifting the conversation
If we evaluate AI solely by how much time or even money it saves, we miss the bigger picture. Efficiency is a commendable goal, but better outcomes for patients are the ultimate prize. Making clinical failure rare is a benefit that compounds across the entire ecosystem: sponsors recover capital that today is written off in late-phase attrition; regulators spend their finite review capacity on assets with a credible chance of approval; investigators and sites are spared the demoralizing work of running trials that were unlikely to succeed; payers and health systems avoid absorbing the downstream cost of therapies that never reach approval; and most importantly, trial participants and the patients waiting behind them are no longer exposed to experimental therapies whose failure was foreseeable. AI's greatest contribution to lowering the total cost of development won't come from making discovery cheaper, it will come from making clinical failure rare.
As leaders in biotechnology and pharmaceuticals, our mission shouldn't just be to build a faster version of the system we already have. Our mission must be to build a smarter one. By moving away from simple automation and leaning heavily into decision intelligence, we won't just bring drugs to market faster—we will bring the right drugs to the right patients with unprecedented precision – that’s best for patients, for researchers, for clinicians, and for the sponsors committed to doing so.
